The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey

The most recent release (May 14, 2026) announces that Justin Kirkland, CSO of Amino Innovations (a subsidiary), will appear on the “The Human Upgrade with Dave Asprey” podcast on June 4, 2026. The release ties the media event to ongoing operational updates: advancement of the BPC-157 transdermal patch toward commercial release, the research collaboration with the University of Alberta’s Drug Development and Innovation Centre (DDIC), and monitoring of U.S. regulatory shifts favorable to peptide therapies.

This news is a routine media booking. It adds no new material information beyond what was already disclosed in the May 7 product update (patch testing progress) and the April 16 regulatory commentary. The podcast aims to build consumer awareness among a targeted audience; however, it does not alter the company’s financial position, development timeline, or commercial prospects in a way that markets would not have already priced in. The partnership with MMA (May 12) was the recent material catalyst; this podcast appearance is a promotional follow-on. There is no unexpected information, no revenue milestone, and no change in the outlook. Therefore, the impact is neutral.

The Precision Peptide Company (CSE: BPC) operates a peptide wellness platform under the Amino Innovations brand. It manufactures and distributes oral peptide products in the U.S. and is developing a needle‑free transdermal patch delivery system. The flagship project is the BPC‑157 transdermal patch, designed to deliver healing/regenerative peptides without injections. A second product, an Immune Defense Patch (Thymosin Alpha‑1), is in the pipeline. Research is conducted in partnership with the University of Alberta’s DDIC. The company’s growth strategy relies on expanding direct‑to‑consumer reach through digital marketing and strategic partnerships, most recently with MMA.INC.